Dividends Inside Welcome to Dividends Inside
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Definium Therapeutics, Inc.
DFTX
$20.87 (+ $0.85 + 4.25%)
Last updated: 2026-05-20 23:43 UTC
About the Company
Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in New York, specializing in the development of psychedelic-derived therapeutics for psychiatric and neurological disorders. Formerly known as MindMed, it focuses on creating scientifically rigorous treatments that target root causes, such as generalized anxiety disorder (GAD), major depressive disorder (MDD), and autism spectrum disorder (ASD), aiming for long-term remission over symptom management. The company's lead candidate, DT120 orally disintegrating tablet (ODT), a proprietary lysergide (LSD) D-tartrate formulation, has FDA Breakthrough Therapy Designation for GAD and is advancing through multiple Phase 3 trials, with topline data anticipated in 2026. Additional pipeline assets include DT402, the R-enantiomer of MDMA, under investigation for ASD to improve social communication via serotonergic mechanisms. Operating in the biotechnology sector of healthcare, Definium Therapeutics employs 74 people and drives innovation in psychoplastogenic drug development to address the mental health crisis. Founded around 2019, it exemplifies precision science applied to psychedelics for scalable healing.
Price History
Latest News for DFTX
Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
NEW YORK, May 12, 2026--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address the underlying causes of psychiatric and neurological disorders, today announced that the first patient has been dosed in Ascend, its second Phase 3 study evaluating DT120 ODT (lysergide tartrate) for the treatment of major depressive disorder (MDD). The Ascend study will evaluate the effi
Definium Therapeutics Announces New Employee Inducement Grants
NEW YORK, May 11, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to five newly hired non-executive employees consisting of options to purchase an aggregate of 255,340 common shares of the Company (the "Options") with effective grant dates of April 27, 2026, M
Definium Therapeutics (DFTX) Deepens Losses Advancing Psychedelic Pipeline Is Its Cash Strategy Still Coherent?
In May 2026, Definium Therapeutics, Inc. reported first quarter results showing a net loss of US$77.1 million, with basic and diluted loss per share from continuing operations of US$0.71, compared with a net loss of US$23.35 million and basic loss per share of US$0.27 a year earlier. This widening loss highlights the company’s increased spending and operating pressure as it advances late‑stage psychedelic‑based therapies for psychiatric and neurodevelopmental disorders without yet generating...
Definium Therapeutics Q1 Earnings Call Highlights
Definium Therapeutics (NASDAQ:DFTX) reported first-quarter 2026 financial results and outlined a series of near-term clinical milestones for its lead candidate, DT120 ODT, during a conference call held May 7. Management described 2026 as a “pivotal year,” with three Phase III top-line readouts expec
Definium (DFTX) Q1 2026 Earnings Transcript
This webcast is live on the Investors section of Mind Medicine (MindMed) Inc.’s website at definiumtx.com, and a replay will be available after the webcast. Leading the call today will be Robert Barrow, our Chief Executive Officer, who is joined by Daniel Karlin, our Chief Medical Officer, Brandi L. Roberts, our Chief Financial Officer, and Matthew Wiley, our Chief Commercial Officer.
Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
NEW YORK, May 07, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company") (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today reported financial results for the quarter ended March 31, 2026, and recent highlights.